Literature DB >> 21990093

Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?

Maria Christina Cox1, Giuseppe Mannino, Luana Lionetto, Virginia Naso, Maurizio Simmaco, Maria Antonietta Aloe Spiriti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21990093     DOI： 10.1002/ajh.22148

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  9 in total

Review 1.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

3.  Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.

Authors:  Neel K Gupta; Chia-Ching Wang; Gabriel N Mannis; John-Paul J Yu; James L Rubenstein
Journal:  Leuk Lymphoma       Date:  2017-04-10

Review 4.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

5.  Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma.

Authors:  Emanuele Cencini; Alberto Fabbri; Umberto Arrigucci; Alfonso Cerase; Monica Bocchia
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-06-16       Impact factor: 2.576

6.  Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient.

Authors:  Matthew K Adams; Christina Y Weng
Journal:  Case Rep Ophthalmol Med       Date:  2019-02-25

7.  Secondary CNS myeloma with remission after systemic CNS-penetrating agents.

Authors:  Luis G Fernandez; Daniel Eduardo Oyon; Vinai Gondi; Sean Grimm; Osaama H Khan
Journal:  Neurooncol Adv       Date:  2022-07-01

8.  Memory loss during lenalidomide treatment: a report on two cases.

Authors:  Adeline Rollin-Sillaire; Xavier Delbeuck; Marianne Pollet; Marie-Anne Mackowiak; Pierre Lenfant; Marie-Pierre Noel; Thierry Facon; Xavier Leleu; Florence Pasquier; Emilie Le Rhun
Journal:  BMC Pharmacol Toxicol       Date:  2013-08-12       Impact factor: 2.483

9.  Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Authors:  Zhimin Li; Yushi Qiu; David Personett; Peng Huang; Brandy Edenfield; Jason Katz; Darius Babusis; Yang Tang; Michael A Shirely; Mehran F Moghaddam; John A Copland; Han W Tun
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.